Observational studyChest2018

Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.

Gerard A Silvestri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.